BioCryst Pharmaceuticals News

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals posted its quarterly earnings results on Tuesday. The company reported earnings per share for the quarter, beating the analysts' consensus estimate of by $0.06, StockRatingsNetwork reports.

"We are pleased that our recent interactions with the FDA have defined a pathway to file a peramivir NDA for regulatory approval in the U.S.," said Jon P. Stonehouse, President & Chief Executive Officer of BioCryst.

The "patent cliff", which refers to the expiration of patent on several blockbuster drugs over the next few years, is having a significant impact on major drug companies' top-lines. According to estimates from EvaluatePharma, in 2013 alone, patents on drugs with annual sales of nearly $29 billion will expire.

April was a month that kept our reporters and editors busy chasing down stories that could have a major economic impact on our region in the coming years.

We've been seeing a lot of new activity in BioCryst Pharmaceuticals , which we last covered on April 7th following a 42% run in the stock chasing the good news that the company received from the FDA about its antiviral agent peramivir .

BioCryst Pharmaceuticals Inc. traded in the range of $1.75 and $1.97 during its latest trading session.

That flu has led to the approval of BioCryst 's flu treatment peramivir in China, despite the drug's failure to meet endpoints in its FDA trial.